Overcoming resistance to Herceptin?
Meet the Experts
Andrew D. Seidman, M.D. is an attending physician for the Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, and a professor of medicine, Joan and Sanford I. Weill Medical College of Cornell University.
Jennifer Armstrong, M.D. is a breast cancer oncologist at Paoli Hematology-Oncology Associates in Paoli, Pa., with a special interest in physicians' communication skills.
Question from Joan: Dr. Seidman, what are the available and under-investigation options to overcome resistance to Herceptin?
- Answer —Andrew Seidman, M.D.: Currently, the only agent that has been shown to improve the effectiveness of conventional therapy in Herceptin resistant breast cancer is Tykerb, or lapatinib, based on the trial we spoke of earlier. Another promising agent reported by my colleague Dr. Shanu Modi at the ASCO meeting this spring is an agent known as 17AAG. This is also known as KOS-953. This novel agent inhibits a molecule known as heat-shock protein 90 and causes degradation of the HER2 receptor. Dr. Modi reported responses with this agent in combination with Herceptin in patients whose cancer had recently progressed on other chemotherapy with Herceptin. There is also data from Dr. Storniolo from the San Antonio Breast Cancer Symposium in December 2005 demonstrating the role for Tykerb and this might perhaps in the future be observed with other tyrosine kinase inhibitors. We have also studied Cox-2 inhibitors, such as Celebrex (chemical name: celecoxib), based on laboratory evidence, but unfortunately found no evidence that this strategy had any effectiveness in Herceptin-resistant breast cancer. Other strategies under investigation include tumor vaccines, the agent pertuzimab, which is a monoclonal antibody targeting a different portion of the HER2 receptor than Herceptin, among others.
On Wednesday, July 19, 2006, our Ask-the-Expert Online Conference was called Targeted Therapies: What is Right for You?Andrew Seidman, M.D. and moderator Jennifer Armstrong, M.D. answered your questions about different kinds of targeted therapies and how they work.
The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.
An original video-on-demand educational initiative brought to you by Breastcancer.org and Comcast. Visit www.comcast.net/pinkribbon each week through the end of October for engaging, up-to-date videos and information about the fight to end breast cancer.